The editorialists reply

New England Journal of Medicine

Volumn 370, Issue 18, 2014, Pages 1768-1769

  Himmelfarb, Jonathan ^a   Tuttle, Katherine R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE METHYL; PLACEBO; DRUG DERIVATIVE; OLEANOLIC ACID;

CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION; HUMAN; KIDNEY DISEASE; LETTER; PATIENT SAFETY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; FEMALE; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; OLEANOLIC ACID; RENAL INSUFFICIENCY, CHRONIC;

EID: 84899750650     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1400872     Document Type: Letter

References (3)

1. Collins FS. Reengineering translational science: the time is right. Sci Transl Med 2011;3:90cm17.
2. Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012;490:187-91.
3. Djulbegovic B, Hozo I, Ioannidis JP. Improving the drug development process: more not less randomized trials. JAMA 2014; 311:355-6.